Free shipping on all orders over $ 500

LY303511

Cat. No. M4852

All AbMole products are for research use only, cannot be used for human consumption.

LY303511 Structure
Size Price Availability Quantity
5mg USD 100 In stock
10mg USD 160 In stock
50mg USD 680 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LY303511, like rapamycin, inhibited mTOR-dependent phosphorylation of S6K, but not PI3K-dependent phosphorylation of Akt. LY303511 blocked proliferation in A549 as well as in primary pulmonary artery smooth muscle cells, without causing apoptosis. In contrast to rapamycin, LY303511 reduced G(2)/M progression as well as G(2)/M-specific cyclins in A549 cells. Consistent with an additional mTOR-independent kinase target, LY303511 inhibited casein kinase 2 activity, a known regulator of G(1) and G(2)/M progression. In addition to its antiproliferative effect in vitro, LY303511 inhibited the growth of human prostate adenocarcinoma tumor implants in athymic mice. Given its inhibition of cell proliferation via mTOR-dependent and independent mechanisms, LY303511 has therapeutic potential with antineoplastic actions that are independent of PI3K inhibition.

Chemical Information
Molecular Weight 306.36
Formula C19H18N2O2
CAS Number 154447-38-8
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Bodenstine TM, et al. Cancer Res. Homotypic gap junctional communication associated with metastasis suppression increases with PKA activity and is unaffected by PI3K inhibition.

[2] Shenoy K, et al. Cancer Res. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors.

[3] Kristof AS, et al. J Pharmacol Exp Ther. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.

[4] El-Kholy W, et al. FASEB J. The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism.

Related mTOR Products
AZD8055

AZD8055 is a novel ATP-competitive inhibitor of mTOR kinase (both complexes mTORC1 and mTORC2) with an IC50 of 0.8 nM.

Deforolimus

Deforolimus (also known as AP23573 and MK-8669) is an investigational targeted and small-molecule mTOR inhibitor. *The compound is unstable in solutions, freshly prepared is recommended

Everolimus

Everolimus (RAD001) also known as SDZ-RAD and Certican is an mTOR inhibitor with IC50 of 0.63 nM.

KU-0063794

KU-0063794 is a potent and selective mTOR inhibitor with IC50 values of approximately 10 nM for mTORC1 and mTORC2.

WYE-354

WYE-354 is a cell-permeable pyrazolopyrimidine compound that acts as a potent and ATP-competitive mTOR inhibitor (IC50 = 5 nM with S6K as the substrate and 100 µM ATP).

  Catalog
Abmole Inhibitor Catalog




Keywords: LY303511 supplier, mTOR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.